COPN 📈 COSMO Pharmaceuticals SA - Overview

Exchange: SW • Country: Ireland • Currency: CHF • Type: Common Stock • ISIN: NL0011832936

COPN: Gastroenterology, Dermatology, Healthtech, Pharmaceuticals, Medicines

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, a submucosal injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin SV MMX ' IBS-D, a formulation that is in Phase III clinical trial to treat colonic infections and irritable bowel syndrome with diarrhoea; CB-03-10, an oral androgen receptor antagonist, which is in Phase I clinical trial for treatment solid tumors; CB-01-33 that is in preclinical studies for the treatment of bile acid diarrhea; and CB-01-35, an enema solution, which is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, RedHill Biopharma Ltd., Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland. Web URL: https://www.cosmopharma.com

Additional Sources for COPN Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

COPN Stock Overview

Market Cap in USD 1,136m
Sector Healthcare
Industry Drug Manufacturers - General
GiC Sub-Industry Pharmaceuticals
IPO / Inception

COPN Stock Ratings

Growth 5y -17.3%
Fundamental 88.4%
Dividend 47.9%
Rel. Strength Industry 2064
Analysts -
Fair Price Momentum 63.35 CHF
Fair Price DCF 183.79 CHF

COPN Dividends

Dividend Yield 12m 2.82%
Yield on Cost 5y 2.51%
Annual Growth 5y 25.84%
Payout Consistency 38.0%

COPN Growth Ratios

Growth Correlation 3m -89.1%
Growth Correlation 12m 29.6%
Growth Correlation 5y -47%
CAGR 5y -2.31%
CAGR/Mean DD 5y -0.08
Sharpe Ratio 12m 0.64
Alpha -1.65
Beta 0.68
Volatility 26.03%
Current Volume 19.9k
Average Volume 20d 13.3k
What is the price of COPN stocks?
As of January 08, 2025, the stock is trading at CHF 64.60 with a total of 19,897 shares traded.
Over the past week, the price has changed by +1.41%, over one month by +5.38%, over three months by -13.52% and over the past year by +13.53%.
Is COSMO Pharmaceuticals SA a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, COSMO Pharmaceuticals SA (SW:COPN) is currently (January 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 88.38 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of COPN as of January 2025 is 63.35. This means that COPN is currently overvalued and has a potential downside of -1.93%.
Is COPN a buy, sell or hold?
COSMO Pharmaceuticals SA has no consensus analysts rating.
What are the forecast for COPN stock price target?
According to ValueRays Forecast Model, COPN COSMO Pharmaceuticals SA will be worth about 69.7 in January 2026. The stock is currently trading at 64.60. This means that the stock has a potential upside of +7.94%.
Issuer Forecast Upside
Wallstreet Target Price 97.7 51.2%
Analysts Target Price - -
ValueRay Target Price 69.7 7.9%